Predicting recurrence and progression in non-muscle-invasive bladder cancer using European Organization of research and treatment of cancer risk tables

Urology Journal

Volumn 6, Issue 3, 2009, Pages 189-193

  Ather, M Hammad ^a   Zaidi, Masooma ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

Disease progression; Neoplasm recurrence; Risk; Urinary bladder neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER TUMOR; DISEASE COURSE; FEMALE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS;

EID: 70349775538     PISSN: 17351308     EISSN: 1735546X     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Ferlay J, Bray F, Pisani P, Parkin DM. Globcan 2002, Cancer Incidence, Mortality and Prevalence Worldwide, IARC CancerBase No 5, version 2.0. Lyon: IARCC Press; 2004.
2. Jamal S, Moghal S, Mamoon N, Mushtaq S, Luqman M, Anwar M. The pattern of malignant tumours: tumour registry data analysis, AFIP, Rawalpindi, Pakistan (1992-2001). J Pak Med Assoc. 2006;56:359-62.
3. Bhurgri Y, Bhurgri A, Hasan SH, et al. Cancer patterns in Karachi division (1998-1999). J Pak Med Assoc. 2002;52:244-6.
4. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130:1083-6.
5. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000;164:680-4.
6. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-5.
7. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging Manual. 6th ed. New York: Springer Verlag; 2002.
8. European Organization for Research and Treatment of Cancer [homepage on the Internet]. EORTC risk tables for predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer [cited 2009 Aug 1]. Available form: http://www.eortc.be/tools/bladdercalculator/.
9. Fujii Y, Fukui I, Kihara K, Tsujii T, Kageyama Y, Oshima H. Late recurrence and progression after a long tumor-free period in primary Ta and T1 bladder cancer. Eur Urol. 1999;36:309-13.
10. Fujikawa K, Matsui Y, Kobayashi T, et al. Predicting disease outcome of non-invasive transitional cell carcinoma of the urinary bladder using an artificial neural network model: results of patient follow-up for 15 years or longer. Int J Urol. 2003;10:149-52.
11. Rodriguez Alonso A, Pita Fernandez S, Gonzalez-Carrero J, Nogueira March JL. [Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67]. Actas Urol Esp. 2003;27:132-41. Spanish.
12. Kramer MW, Kuczyk MA, Hennenlotter J, et al. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer. Oncol Rep. 2008;20:1403-8.
13. Baak JP, Bol MG, van Diermen B, Janssen EA, Buhr-Wildhagen SB, Mestad O, Øgreid P, Kjellevold KH. DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality. Urology. 2003;61:1266-72.
14. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou J. Guidelines on TaT1 (non-muscle invasive) bladder cancer. Arnhem (The Netherlands): European Association of Urology (EAU); 2008.